Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
https://beta.firstwordpharma.com/story/5240631
JAK inhibitor's seem to be the way forward.. Sareums time is due soon, were tyking all the right boxes ;)
https://beta.firstwordpharma.com/story/5241465
The news on BRII-196 and BRII-198 comes shortly after GlaxoSmithKline and Vir Biotechnology said that another arm of the ACTIV-3 study investigating VIR-7831 in hospitalised adults with COVID-19 will be closed to enrolment as the benefit of the dual-action SARS-CoV-2 monoclonal antibody may be less than expected.
1801 - tick tock, and we continue to wait patiently....
While Sareum may lag its peers in developing a cure for COVID-19, the company is a cancer treatment leader based on TYK2/JAK1 inhibitors, which hold significant potential for its shareholders.
https://www.asktraders.com/analysis/sareum-sar-shares-are-down-29-9-in-2021-is-there-hope-for-a-rally-soon/
Have a great weekend all
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srra/sierra-oncology/news/do-institutions-own-sierra-oncology-inc-nasdaqsrra-shares
and we wait patiently
H1, yes the conclusion sums it up..
The study shows the importance of protein-protein interactions and network analysis in uncovering how proteins behave during SARS-CoV-2 infection in lung cancer patients. The ten hub genes common to both conditions were identified.
Most of these genes encode proteins intimately involved in biological pathways. This knowledge may advance the understanding of COVID-19, lung cancer, and therapies against both these conditions.
More on the cytokine storm
https://www.earlham.ac.uk/newsroom/could-our-immune-system-be-why-covid-19-so-deadly#AboutQuadramInstitute-3
More on the cytokine storm
https://www.earlham.ac.uk/newsroom/could-our-immune-system-be-why-covid-19-so-deadly#AboutQuadramInstitute-3
https://www.frontiersin.org/articles/10.3389/fimmu.2021.629193/full
Funding supported by the UKRI Biotechnological and Biosciences Research Council (BBSRC)
Azz, it will move when the news drops, 50k buy Thursday, someone's in the know..
waiting's the hardest part, fingers crossed all goes well with 1801. 737 news could drop anytime.
set my targets, just need results
https://pharmaphorum.com/news/lilly-cuts-a-960m-deal-with-rigel-on-rip-kinase/
Nice 125m upfront;)
GLALTH's
https://medicalxpress.com/news/2021-02-retooling-small-molecule-kinase-inhibitors.html
fingers tapping time, never want to rush my life away, but cant wait for the preclinical results
Now, together with Abbott, the pharmaceutical company producing fenofibrate, he is involved in Phase III, placebo-controlled, double-blind studies that are already taking place in clinical centers in Israel, South America, the United States and Europe.
“It will take several months,” he told the Post. “But at the end, we will know if we have a drug that can deal with coronavirus.”
6 months for Israel, looks like they have a similar drug to 1801... but there's plenty room for 2 ;)
P2
Arber said that other leading hospitals from Brazil, the Czech Republic and other places around the world have also reached out.
“This is an innovative treatment that can be produced quickly and efficiently at a low cost,” Arber explained. “Even if the vaccines do what they are supposed to, and even if no new mutations are produced, then still, in one way or another, coronavirus will remain with us.”
He said he does not know how long it will take, but “my drug can be produced rapidly, efficiently and reliably, and at a low cost.”
Wrestling back control from COVID
Finally, Hebrew University’s Nahmias believes he could downgrade COVID-19’s severity into nothing worse than a common cold, by using the FDA-approved drug Fenofibrate.
His technology, licensed by Tissue Dynamics, a drug development company, permits rapid discovery of new therapeutics.
“Viruses are parasites,” Nahmias explained. “They cannot replicate by themselves. They have to get inside a human cell and hijack their machinery to replicate.”
Nahmias research with collaborators at Mount Sinai Hospital demonstrated that the novel coronavirus prevents the burning of fat in lung cells, resulting in large amounts of fat accumulating inside lung cells – a condition the virus needs to reproduce. Fenofibrate, according to his published data, reversed that effect and eliminated virus replication in less than five days of treatment.
“By understanding how the SARS-CoV-2 controls our metabolism, we can wrestle back control from the virus and deprive it of the very resources it needs to survive,” Nahmias said, noting that it also may help explain why patients with high blood sugar and cholesterol levels are often at a particularly high risk to develop COVID-19.
Nahmias, working with Sourasky and Hadassah medical centers, gathered and evaluated retrospective data on over 20,000 patients. This data showed the several dozen COVID-19 patients who were taking fibrates were protected from the virus, confirming his laboratory results
“We looked at 20,000 patients; out of them, we screened out all patients who didn’t have blood measurements, were not hospitalized, or were not over 18 years old,” he explained. “We ended up with around 3,000 patients. And when you look at the population that took fibrates and compared it to a... population that did not take fibrates, you see something very interesting.
“Even though the risk factors for the fibrates group are slightly higher, all the main indicators are down,” he continued. “Patients that took fibrates were five days less in the hospital, had ICU admission rates drop from 44% to 7%. And their survival rate increased to about 100%.
“Within four to five days, for these patients, the pneumonia was gone,” he said. “Inflammation disappeared incredibly fast.”
Now, together with Abbott, the pharmaceutical company producing fenofibrate, he is involved in Phase III, placebo-controlled, double-blind studies that are already taking place in clinical cent